Indian Immunologicals launches classical swine fever vaccine under Brand name 'Raksha Class'

The classical swine fever is a highly contagious viral disease of pigs caused by an RNA virus and has a high fatality rate, it added.

Published On 2020-05-31 04:30 GMT   |   Update On 2020-05-31 04:30 GMT

New Delhi: Vaccine maker Indian Immunologicals Limited on Thursday said it has launched classical swine fever vaccine for pigs in the country.

This cell culture technology-based vaccine has been developed in collaboration with the Indian Veterinary Research Institute (IVRI), Bareilly, Indian Immunologicals Limited (IIL) said in a statement.

The classical swine fever is a highly contagious viral disease of pigs caused by an RNA virus and has a high fatality rate, it added.

Advertisement

The company, however, did not provide any details about the price of the vaccine.

The current requirement of a vaccine for this disease is about 220 lakh doses and the supply is less than 10 lakh doses, IIL said.

The company's vaccine under the brand name ''Raksha Class'' offers distinct advantages in terms of safety and can be scaled up in cell cultures to meet the entire country's requirements, it added.

Advertisement

"The classical swine fever is one of the major diseases of pigs in India. It causes a loss of about Rs. 400 crore per annum in India. The disease has led to a decrease of the pig population in the country.

With the launch of Raksha Class, we can ensure that the pig population in India can be increased, and hence, the growers will be immensely benefited economically," IIL Managing Director K Anand Kumar said. 

Read also: AstraZeneca secures orders for 400 million doses of COVID-19 vaccine


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News